<code id='371C969257'></code><style id='371C969257'></style>
    • <acronym id='371C969257'></acronym>
      <center id='371C969257'><center id='371C969257'><tfoot id='371C969257'></tfoot></center><abbr id='371C969257'><dir id='371C969257'><tfoot id='371C969257'></tfoot><noframes id='371C969257'>

    • <optgroup id='371C969257'><strike id='371C969257'><sup id='371C969257'></sup></strike><code id='371C969257'></code></optgroup>
        1. <b id='371C969257'><label id='371C969257'><select id='371C969257'><dt id='371C969257'><span id='371C969257'></span></dt></select></label></b><u id='371C969257'></u>
          <i id='371C969257'><strike id='371C969257'><tt id='371C969257'><pre id='371C969257'></pre></tt></strike></i>

          focus

          focus

          author:leisure time    Page View:12117

          Is there a cure for allergies? Has the FDA become too flexible? And which drugs make you muscular?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Recorded live from from the STAT Breakthrough Summit East in New York City, we discuss some event highlights, including words from CRISPR pioneer Feng Zhang and Regeneron Pharmaceuticals head scientist George Yancopoulos. We also discuss the latest news in the life sciences, including a twist in the GLP-1 story, the cost of gene therapy, and, of course, pie.

          advertisement

          For more on what we cover, here’s our full Summit coverage; here’s more on Medicare and GLP-1s; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          Wikipedia

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          What will Novo Nordisk's VC do with its influx of cash?
          What will Novo Nordisk's VC do with its influx of cash?

          LISELOTTESABROE/Scanpix/AFPviaGettyImagesTheDanishpharmaceuticalcompanyNovoNordiskhasshepherdedallki

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

          MarkJ.Terrill/APAfollow-upstudyofafirst-of-its-kindcancertreatmentmayreflectsystemicbiases,theFoodan